share_log

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality

股東可以相信神經分泌生物科學(NASDAQ:NBIX)的收益質量很高
Simply Wall St ·  11/08 20:45

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) strong earnings report was rewarded with a positive stock price move. Our analysis found some more factors that we think are good for shareholders.

Neurocrine Biosciences, Inc. 's(納斯達克股票代碼:NBIX)強勁的收益報告獲得了股價的積極走勢的回報。我們的分析發現了更多我們認爲對股東有利的因素。

big
NasdaqGS:NBIX Earnings and Revenue History November 8th 2024
NASDAQGS: NBIX 收益和收入歷史記錄 2024 年 11 月 8 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

Importantly, our data indicates that Neurocrine Biosciences' profit was reduced by US$168m, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Neurocrine Biosciences to produce a higher profit next year, all else being equal.

重要的是,我們的數據表明,由於不尋常的項目,Neurocrine Biosciences的利潤比去年減少了1.68億美元。儘管由於不尋常項目而產生的扣除首先令人失望,但有一線希望。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。而且,畢竟,這正是會計術語的含義。假設這些不尋常的支出不會再次出現,因此,我們預計Neurocrine Biosciences在其他條件相同的情況下,明年將實現更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以點擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Neurocrine Biosciences' Profit Performance

我們對Neurocrine Biosciences盈利表現的看法

Because unusual items detracted from Neurocrine Biosciences' earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Neurocrine Biosciences' earnings potential is at least as good as it seems, and maybe even better! And on top of that, its earnings per share have grown at an extremely impressive rate over the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So if you'd like to dive deeper into this stock, it's crucial to consider any risks it's facing. You'd be interested to know, that we found 3 warning signs for Neurocrine Biosciences and you'll want to know about these.

由於不尋常的項目削弱了Neurocrine Biosciences去年的收益,因此你可以爭辯說,我們可以預期本季度的業績會有所改善。因此,我們認爲Neurocrine Biosciences的盈利潛力至少和看起來一樣好,甚至可能更好!最重要的是,其每股收益在過去一年中以極其驚人的速度增長。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。因此,如果你想更深入地研究這隻股票,那麼考慮它面臨的任何風險至關重要。你可能會有興趣知道,我們發現了 Neurocrine Biosciences 的 3 個警告信號,你會想知道這些信號的。

This note has only looked at a single factor that sheds light on the nature of Neurocrine Biosciences' profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

這份報告只研究了揭示Neurocrine Biosciences利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份擁有大量內幕持股的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論